News and new events of SK Biopharmaceuticals
SK Biopharmaceuticals Inks Research Collaboration Agreement with ProEn Therapeutics Further Accelerating Expansion of Oncology Research and Pipeline for Global Competitiven....
SK Biopharmaceuticals Seals 1st Actinium-225-Based Collaborative Research Agreement with Korea Institute of Radiological and Medical Sciences as Steps Toward Becoming Global Radio....
[Translated ver.] SK Biopharmaceuticals’ Partner Eurofarma Submits Prioritized NDA for Cenobamate in Brazil Korea and Brazil, Oct. 8, 2024 – ....
SK Biopharmaceuticals, Full-Life Technologies Enter Licensing Agreement for Novel Therapeutic Targeting Multiple Solid Tumors SK Biopharmaceuticals, Full-Life Technologies se....
Mobilizing at 2024 Bio SK Biopharmaceuticals has mobilized its U.S. subsidiaries SK Life Science, Inc. and SK Life Science Labs to promote their busines....
SK Biopharmaceuticals Posts 2024 Q1 Turnaround, Setting the Stage for Annual Profit Sales reach KRW 114 billion, operating profit hits KRW 10.3 billion XCOPRI®....
SK Biopharmaceuticals Announces 100,000 Patients Globally Have Been Treated with Cenobamate Through Sales of XCOPRI® and ONTOZRY® in the U.S., Europe, Israel, and Canada ....
Ready for 2nd Take Off SK Biopharmaceuticals CEO Donghoon Lee presents its 2024 strategy at SK Life Science's annual National Sales Meeting in Tampa, Florida,....
Reaffirming Vision Donghoon Lee, CEO of SK Biopharmaceuticals, gives a presentation to global investors at J.P. Morgan Healthcare Conference in San Fran....
Getting Cenobamate Ready for 30 More Markets Donghoon Lee, CEO of SK Biopharmaceuticals, left, holds an agreement with Min-young Kim, President of Dong-A ST, afte....
